30 Jan NexPlasmaGen to present at the 2022 OBIO investment summit
NEXPLASMAGEN TO PRESENT AT THE 2022 OBIO INVESTMENT SUMMIT
Canada’s Premier Health Science Investment Event!
Montreal/January 30, 2022 – NexPlasmaGen is proud to announce that it is presenting at 2022 OBIO Investment Summit.
The OBIO Investment Summit will be hosted virtually February 9-11, 2022, and NexPlasmaGen was selected to present this year on February 11 at 13h. Over 50 companies selected were assessed by the OBIO Investment Summit review committee of VC investors and strategic partners at this year’s summit and all presenting live to kick off their new funding round.
With more than $1B raised for Summit companies, this Investment Summit brings high value to Canadian companies like NexPlasmaGen and the global investment community.
Investors attending the Summit get the unique opportunity to connecting with Canada’s most investable venture companies as selected by global VC investors and strategic partners, watch presentations live, ask questions, schedule meetings and review recorded presentations, access private virtual meeting rooms during and after the Summit and receive an investment abstract for each company.
“I am excited to present NexPlasmaGen to the OBIO Investment Summit so I can meet investors and strategic partners to close our Seed round and to discuss future partnerships!”, indicated Dr Valérie Léveillé, CEO of NexPlasmaGen.
Ontario Bioscience Innovation Organization (OBIO®) founded in 2009, is a not-for-profit, membership-based organization engaged in strategy, programming, policy development and advocacy to further the commercialization of Ontario’s human health science companies positioning Ontario as a leader in the international marketplace. OBIO advances this goal through collaborative partnerships with industry, the investment community, academia, patients and government.
NexPlasmaGen is striving to converge the emerging field of cold plasma biotechnology for personalized cancer care. We are developing high precision cold plasma delivery systems with the potential to selectively kill cancer cells while sparing surrounding healthy tissue. NexPlasmaGen first application is in breast cancer care, applying its patented cold plasma device to improve patient outcomes in breast conserving therapy.
Valérie Léveillé, CEO/Founder